Clinical Trial: Survey on Epidemiology of Hypoparathyroidism in France
Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Observational [Patient Registry]
Official Title: Epi-Hypo: Survey on Epidemiology of Hypoparathyroidism in France
Brief Summary: Very few data has been published on the epidemiology of hypoparathyroidism worldwide: none exists specifically for France. Hypoparathyroidism could led to complications. Here, the investigators plan to collect data about both epidemiology, medication and complication of hypoparathyroidism in France.
Detailed Summary: Very few data has been published on the epidemiology of hypoparathyroidism worldwide. None exists specifically in France. Hypoparathyroidism could led to complications: e.g. symptomatic hypocalcemia, calcifications (brain, eye and other soft tissues), nephrolithiasis/nephrocalcinosis, renal insufficiency. Here,the investigators plan to collect data about both epidemiology, medication and complication of hypoparathyroidism in France.
Sponsor: European Georges Pompidou Hospital
Current Primary Outcome: Assessment of the epidemiology of patients with hypoparathyroidism in France [ Time Frame: Through study completion, about 2 years ]
Original Primary Outcome: Same as current
Current Secondary Outcome:
- Assessment of the biology at inclusion will describe the evolution of the included population from diagnosis to now (inclusion) [ Time Frame: At inclusion (under treatment): through study completion, about 2 years ]Number of patients with at least one anomaly at biology (calcemia in mM, calciuria in mmol/j, parathormone in pg/ml, creatininemia in µM, phosphatemia in mM, vitamin D in nmol/l & magnesemia in mM) at inclusion
- Assessment of the management at inclusion will describe treatment and complications at inclusion [ Time Frame: At inclusion (under treatment): through study completion, about 2 years ]Number of patients with clinical outcomes (complications such as cataract, nephrolithiasis, nephrocalcinosis, and others) and their management at inclusion
- Assessment of the biology (calcemia, calciuria, parathormone, creatininemia, phosphatemia & magnesemia) at diagnosis and drug therapy at inclusion will describe population [ Time Frame: Through study completion, about 2 years ]Number of patients with at least one anomaly at biology (calcemia in mM, calciuria in mmol/j, parathormone in pg/ml, creatininemia in µM, phosphatemia in mM, vitamin D in nmol/l & magnesemia in mM) at diagnosis
Original Secondary Outcome: Same as current
Information By: European Georges Pompidou Hospital
Dates:
Date Received: July 9, 2016
Date Started: July 2016
Date Completion: December 2018
Last Updated: July 17, 2016
Last Verified: July 2016